Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies

(NZB x NZW)F1 mice spontaneously develop an autoimmune syndrome characterized by a fatal immune complex glomerulonephritis. Administration of monoclonal antibodies specific for an I region gene product (I-Az) of the H-2 haplotype associated with susceptibility to glomerulonephritis in these animals...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1983
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187363/
https://www.ncbi.nlm.nih.gov/pubmed/6578293
_version_ 1782146157479198720
collection PubMed
description (NZB x NZW)F1 mice spontaneously develop an autoimmune syndrome characterized by a fatal immune complex glomerulonephritis. Administration of monoclonal antibodies specific for an I region gene product (I-Az) of the H-2 haplotype associated with susceptibility to glomerulonephritis in these animals produced a remission in female mice with established renal disease. The results demonstrated that anti-I-A therapy stabilized the level of proteinuria and increased the 1-yr survival rate from 10% to greater than 90% in treated animals relative to control mice. These findings may ultimately have therapeutic potential for the treatment of systemic lupus erythematosus.
format Text
id pubmed-2187363
institution National Center for Biotechnology Information
language English
publishDate 1983
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21873632008-04-17 Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies J Exp Med Articles (NZB x NZW)F1 mice spontaneously develop an autoimmune syndrome characterized by a fatal immune complex glomerulonephritis. Administration of monoclonal antibodies specific for an I region gene product (I-Az) of the H-2 haplotype associated with susceptibility to glomerulonephritis in these animals produced a remission in female mice with established renal disease. The results demonstrated that anti-I-A therapy stabilized the level of proteinuria and increased the 1-yr survival rate from 10% to greater than 90% in treated animals relative to control mice. These findings may ultimately have therapeutic potential for the treatment of systemic lupus erythematosus. The Rockefeller University Press 1983-10-01 /pmc/articles/PMC2187363/ /pubmed/6578293 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies
title Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies
title_full Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies
title_fullStr Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies
title_full_unstemmed Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies
title_short Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies
title_sort treatment of (nzb x nzw)f1 disease with anti-i-a monoclonal antibodies
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187363/
https://www.ncbi.nlm.nih.gov/pubmed/6578293

Ejemplares similares